Matches 1 - 50 out of 288 1 2 3 4 5 6 >


Match Document Document Title
US20150157642 COSMETIC METHOD FOR CHANGING THE APPEARANCE OF EYES  
The current application is directed to cosmetic methods for changing the appearance of eyes by causing a retraction of the eyelids so that the eyes appear to be more open and have a wider...
US20140303166 COSMETIC METHOD FOR CHANGING THE APPEARANCE OF EYES  
The current application is directed to cosmetic methods for changing the appearance of eyes by causing a retraction of the eyelids so that the eyes appear to be more open and have a wider...
US20130236557 Oil-in-Oil emulsified polymeric implants containing a hypotensive lipid and related methods  
Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an...
US20150238414 Misoprostol Formulation  
A method of reducing the likelihood of infection requiring use of antibiotics during or after induction of labour in a female, comprises administering intravaginally to the female an insert...
US20150250891 HYALURONIC ACID-BASED DRUG DELIVERY SYSTEMS  
The present invention relates to novel hyaluronic acid (HA) hydrogels comprising vesicles loaded with a drug or a protein or a nucleic acid. The new HA hydrogels provide sustain release...
US20140161863 DRUG DELIVERY METHODS, STRUCTURES, AND COMPOSITIONS FOR NASOLACRIMAL SYSTEM  
A drug insert is configured for use with an implant. The implant is configured for insertion into a lacrimal canaliculus. The drug insert includes a drug core comprising a therapeutic agent and a...
US20130101658 DRUG DELIVERY METHODS, STRUCTURES, AND COMPOSITIONS FOR NASOLACRIMAL SYSTEM  
A drug insert is configured for use with an implant. The implant is configured for insertion into a lacrimal canaliculus. The drug insert includes a drug core comprising a therapeutic agent and a...
US20120283293 Methods of neuroprotection involving Prostaglandin E2 EP4 (PGE2 EP4) receptor activation  
The present invention provides methods for attenuating neuronal inflammation and neuronal damage in case of acute or chronic injury of nerve cells of the central nervous system through...
US20100323978 Non-aqueous oil delivery system for ophthalmic drugs  
The present invention relates to a delivery system for ophthalmic drugs, and more particularly, to a non aqueous oil delivery system. Low concentrations of ophthalmic drugs suspended in an oil...
US20150005260 METHODS FOR THE DETECTION AND THE TREATMENT OF DIASTOLIC DYSFUNCTION  
The present invention relates to methods and kits for detecting diastolic dysfunction in subjects without clinical signs of heart failure.
US20110172177 COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE  
The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a...
US20140323561 Control and repellency of biting flies, house flies, ticks, ants, fleas, biting midges, cockroaches, spiders and stink bugs  
Control and repellency of biting flies, house flies, ticks, ants, fleas, biting midges, cockroaches, spiders and stink bugs is obtained by contact of the insects with at least one of the compounds...
US20130035338 EYELID TREATMENT  
The current application is directed topical treatments that improve facial appearance by causing eyelids to naturally open more widely, or be more fully raised, as well as to treatment of ptosis...
US20120149655 USE OF JASMONATE TO TREAT BLADDER DYSFUNCTION  
A formulation or composition contractility comprising jasmonate for modulating bladder and/or treating bladder dysfunction, particularly an overactive bladder in a mammal, particularly a human and...
US20130197081 INTRAVAGINAL ADMINISTRATION OF MISOPROSTOL  
A method for decreasing likelihood of cesarean section delivery in a female in need thereof, comprises administering, intravaginally, to said female, misoprostol.
US20080090780 Storage stable azadirachtin pesticide formulation  
A storage stable, efficacious pesticide formulation is provided that is dilutable by the user and contains azadirachtin (AZA) and a pyrethrin or pyrethroid (PYR), and optionally an aprotic solvent...
US20140045933 METHODS AND COMPOSITIONS FOR TREATING METABOLIC SYNDROME  
Provided are methods, compositions, systems, and kits for treating metabolic syndrome or a disorder associated with metabolic syndrome, e.g., obesity, dyslipidemia, and/or a diabetic condition,...
US20140314868 PROSTAGLANDIN AND PROSTAMIDE DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF  
Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma.
US20130017268 PROSTAGLANDIN AND PROSTAMIDE DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF  
Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma.
US20130101553 INDUCING INACTIVATION OF FIBROGENIC MYOFIBROBLASTS  
Provided are methods of treating fibrotic conditions in a subject and diagnostic methods for determining fibrosis and appropriate treatments for the fibrosis by the identification of specific...
US20130202704 USE OF MEXIPROSTIL IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE AND/OR OF IRRITABLE BOWEL SYNDROME  
The invention relates to the use of mexiprostil in the treatment and/or prevention of inflammatory bowel disease and of irritable bowel syndrome, to the combinations of mexiprostil with other...
US20120259008 METHOD FOR TREATING ASTHENOPIA  
The present invention relates to a method for treating asthenopia, accommodative dysfunction or ocular pain comprising an administration of a specific prostaglandin compound to a mammalian...
US20110281853 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING ATRIAL FIBRILLATION  
The present invention provides compositions and methods for treating or preventing atrial fibrillation (AF). In particular, the present invention provides administration of muscarinic receptor...
US20120225938 METHOD FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS  
The present invention provides a method for treating a central nervous system disorder in a mammalian subject, which comprises administering an effective amount of a 11-deoxy-prostaglandin...
US20130028883 Treatment of ischemic episodes and cerebroprotection through Misoprostol  
The present invention provides compositions and methods for treating an ischemic episode using misoprostol alone or in combination with anti-thrombotic agents.
US20150190359 STABLE LIPOSOMAL FORMULATIONS FOR OCULAR DRUG DELIVERY  
A stable liposomal formulation for ocular delivery. The formulation contains a liposome that includes at least one lipid bilayer containing a phosphatidylcholine, and a prostaglandin F2α...
US20140213646 Sustained Release Formulations for the Treatment of Intraocular Pressure or Glaucoma  
The present embodiments provide for methods of treating elevated intraocular pressure or glaucoma using a sustained release medicament consisting of prostaglandin in benzyl benzoate that is...
US20110275711 METHOD FOR TREATING MACULAR EDEMA  
Provided is a method for treating macular edema in a mammalian subject, comprising administering an effective amount of a fatty acid derivative to the subject in need thereof. The method of the...
US20150018400 TREATMENT OF INFLAMMATORY BOWEL DISEASE  
Disclosed herein is a method comprising administering a compound to a mammal suffering from an inflammatory bowel disease for the treatment of said disease, said compound having a structure...
US20150025020 SELF-PRESERVED OIL DISPERSIONS COMPRISING BORIC ACID  
The present invention relates to a self-preserved oil dispersion. Especially, the present invention relates to a self-preserved oil dispersion including a dispersed oil phase, an aqueous phase and...
US20140371147 COMBINATION OF A PROSTAGLANDIN RECEPTOR AGONIST AND AN MC1R RECEPTOR AGONIST FOR THE TREATMENT AND/OR PREVENTION OF PIGMENTATION DISORDERS  
A combination of compounds is described for the treatment and/or prevention of skin conditions linked to hypopigmentation. Also described, is a combination product that includes at least one...
US20090318549 COMBINATION TREATMENT OF GLAUCOMA  
The methods described herein provide reduction of intraocular pressure by administering a sustained release formulation including latanoprost and a pharmaceutically acceptable vehicle and...
US20120225939 Use of Prostaglandins F2Alpha and Analogues for the Healing of Corneal and Conjunctival Lesions  
The invention relates to a composition for use in treating corneal and conjunctival lesions, wherein the composition comprises a prostaglandin F2alpha or analogue, in a therapeutic amount, said...
US20140350103 SUSTAINED RELEASE DELIVERY OF ACTIVE AGENTS TO TREAT GLAUCOMA AND OCULAR HYPERTENSION  
A method of decreasing intraocular pressure (IOP) in an eye of a patient in need thereof includes implanting a first lacrimal implant through a firsts punctum and into a first lacrimal canaliculus...
US20110118349 USE OF PROSTAGLANDINS F2ALPHA AND ANALOGUES FOR THE HEALING OF CORNEAL AND CONJUNCTIVAL LESIONS  
A composition for use in treating corneal and conjunctival lesions, includes a prostaglandin F2alpha or analogue, in a therapeutic amount, the composition being in a form suitable for topical...
US20150132358 PUNCTAL PLUG WITH ACTIVE AGENT  
A method and apparatus for administering an active agent such as a medicine to a subject, uses an ocular implant such as a punctal plug, to which the active agent has been applied. The implant is...
US20090155338 Chronotherapeutic Ocular Delivery System Comprising a Combination of Prostaglandin and a Beta-Blocker for Treating Primary Glaucoma  
Chronotherapeutic delivery system for treating primary open-angle glaucoma, comprising a delivery system incorporating pharmaceutical products for delivery to an eye in the treatment of primary...
US20110152264 METHOD AND COMPOSITION FOR TREATING OCULAR HYPERTENSION AND GLAUCOMA  
The present invention relates to an ophthalmic aqueous composition containing PGF2α analogues for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and...
US20110245172 BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS  
The present invention relates to biocompatible oligomer-polymer compositions for the in situ formation of implants, wherein the implants release a bioactive agent, a metabolite, or a prodrug...
US20120288485 USE OF JASMONE FOR MODULATING MELATONIN PRODUCTION AND CALCIFICATION OF THE PINEAL GLAND  
A formulation, composition or combination of substances comprising jasmonate for modulating melatonin production and/or calcification of a pineal gland and/or modulation and/or treatment of...
US20130005737 COMPOSITIONS, METHODS AND KITS FOR TREATING LEUKEMIA  
Compositions, kits and methods for treating leukemia in a subject (e.g., human) include a first anti-cancer drug consisting of: Δ12-prostaglandin J3 or a derivative thereof, or a prostaglandin D...
US20130172268 DRUG DELIVERY THROUGH HYDROGEL PLUGS  
An embodiment is a medical prosthesis for blocking or reducing tear flow through a punctum or canaliculus of a human eye and delivering a drug to the eye that comprises a dehydrated covalently...
US20150246044 NEW THERAPEUTIC APPROACHES FOR TREATING PARKINSON'S DISEASE  
The present invention relates to compositions and methods for the treatment of Parkinson's disease and related disorders. More specifically, the present invention relates to novel combinatorial...
US20150231251 COMPOSITIONS AND METHODS FOR TOPICAL DELIVERY OF PROSTAGLANDINS TO SUBCUTANEOUS FAT  
Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid ester (e.g., isopropyl myristate), optionally comprising an ointment base such as...
US20150105462 COMPOSITIONS AND METHODS FOR TOPICAL DELIVERY OF PROSTAGLANDINS TO SUBCUTANEOUS FAT  
Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid ester (e.g., isopropyl myristate), optionally comprising an ointment base such as...
US20090088473 METHOD FOR SCREENING OF PROSTAGLANDIN COMPOUNDS COMPRISING AN OPTIMAL FORMULATION FOR THE ENHANCEMENT OF HAIR GROWTH AND THE STIMULATION OF FOLLICULAR ANAGEN AND FORMULATIONS RESULTING THEREFROM  
A method for developing Prostaglandin F2α analogs for enhancing and sustaining the growth of eye lashes. The exemplary method first provides a method for determining the ability of a FP receptor...
US20150157563 OCULAR COMPOSITION AND METHOD  
An ocular composition can include a polymer matrix and an antibiotic dispersed in the polymer matrix. The polymer matrix can contain a thiolated hyaluronic acid moiety cross-linked to a second...
US20120232139 COMPOSITION FOR OCULAR TOPICAL ADMINISTRATION TREATMENT OCULAR HYPERTENSION AND GLAUCOMA  
The present invention provides a composition for ocular topical administration for treating ocular hypertension and glaucoma, comprising latanoprost as an active ingredient, and (a) a polyol...
US20130261179 Stabilised Prostaglandin Composition  
A pharmaceutical delivery device, such as a suppository or pessary, comprises a synthetic prostaglandin PGE1 analogue (e.g. misoprostol) in a solid polyurethane hydrogel.
US20140371304 METHOD FOR SUPPRESSING TUMORIGENICITY OF STEM CELLS  
A method for suppressing tumorigenicity of stem cells in a mammalian subject, which comprises administering an effective amount of a fatty acid derivative and a method for suppressing...

Matches 1 - 50 out of 288 1 2 3 4 5 6 >